MicroTransponder Inc. This innovative technology is the result of decades of neuroscience research and aims to address chronic neurologic conditions. Their flagship product, the Vivistim® System, is the first FDA-approved system on the Paired VNS platform for the treatment of post-stroke upper limb impairment.

The Paired VNS therapy offers promising results within just six weeks, which can last for years. MicroTransponder is dedicated to expanding access to Vivistim for all stroke survivors and continuously pushing the limits of Paired VNS for other neurological conditions. To learn more about their groundbreaking solutions, visit Vivistim.

com. MicroTransponder Inc. They have patent rights for their cutting-edge technology.

For comprehensive safety information regarding the Vivistim System, please refer to www. vivistim. com/safety.

Individual outcomes may vary, and copyrights for MicroTransponder Inc., its products, and logos are reserved